Francis Martin
PhD
Professor
👥Biography 个人简介
Francis Martin has contributed to nanoparticle drug delivery research for cancer applications, including work on liposomal formulations and their interactions with biological systems. Liposomal doxorubicin (Doxil) was the first FDA-approved cancer nanomedicine, reducing cardiotoxicity through preferential tumor accumulation via the EPR (enhanced permeability and retention) effect, demonstrating the clinical potential of liposomal nanomedicine.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Francis Martin 的研究动态
Follow Francis Martin's research updates
留下邮箱，当我们发布与 Francis Martin（University of Central Lancashire）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment